FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Hydroxyzine Pamoate Oral Capsules
Status: Currently in Shortage
»Date first posted: 03/12/2019
»Therapeutic Categories: Psychiatry

Expand all

Heritage Pharma (New 11/15/2019)

Company Contact Information:
855-228-9470

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Hydroxyzine Pamoate Caps 25 mg 100 count (NDC 14539-674-01) Available Other
Hydroxyzine Pamoate Caps 25 mg 500 count (NDC 14539-674-05) Available Other
Hydroxyzine Pamoate Caps 50 mg 100 count (NDC 14539-675-01) Available Other
Hydroxyzine Pamoate Caps 50 mg 500 count (NDC 14539-675-05) Available Other

Impax Laboratories (Revised 07/24/2019)

Company Contact Information:
877-835-5472

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Hydroxyzine Pamoate 25mg Cap 100ct (NDC 00115-1803-01) On allocation. Anticipated to be fully available in October 2019 Other
Hydroxyzine Pamoate 25mg Cap 500ct (NDC 00115-1803-02) On allocation. Anticipated to be fully available in October 2019 OIther
Hydroxyzine Pamoate 50mg Cap 100ct (NDC 00115-1804-01) On allocation. Anticipated to be fully available in October 2019 Other
Hydroxyzine Pamoate 50mg Cap 500ct (NDC 00115-1804-02) On allocation. Anticipated to be fully available in October 2019 Other

Pfizer Pharmaceuticals (New 12/05/2019)

Company Contact Information:
800-533-4535

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Vistaril (Hydroxyzine Pamoate Oral Capsules) 25 mg Capsules; 100 count bottle (NDC 0069-5410-66) Next delivery and Estimated recovery: July 2020 Shortage per manufacturer: Manufacturing Delay Other
Vistaril (Hydroxyzine Pamoate Oral Capsules) 50 mg Capsules; 100 count bottle (NDC 0069-5420-66) Available Other

Sandoz (Reverified 12/04/2019)

Company Contact Information:
800-525-8747

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 mg 100 count (NDC 0185-0674-01) Limited monthly supply through September due to increase in demand. Working to increase production to meet current demand. Demand increase for the drug
25 mg 500 count (NDC 0185-0674-05) Limited monthly supply through September due to increase in demand. Working to increase production to meet current demand. Demand increase for the drug

Teva Pharmaceuticals (Reverified 12/04/2019)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg 100 count (NDC 0555-0324-02) Available Other
25 mg 100 count (NDC 0555-0323-02) Available Other
25 mg 500 count (NDC 0555-0323-04) Available Other
50 mg 100 count (NDC 0555-0302-02) Available Other
50 mg 500 count (NDC 0555-0302-04) Available Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English